Tanespimycin

Generic Name: Tanespimycin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₃₁H_₄₃N_₃O_₈

CAS Number: 75747-14-7

Unique Ingredient Identifier: 4GY0AVT3L4

Background: Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90). It is developed for the treatment of several types of cancer, solid tumors or chronic myelogenous leukemia.

Indication: Investigated for use/treatment in leukemia (myeloid) and solid tumors.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: tanespimycin

First Posted Date: 2007-12-20

Last Posted Date: 2014-07-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT00577889

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma

Phase 1

Terminated

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Intraocular Lymphoma
Nodal Marginal Zone B-cell Lymphoma
Post-transplant Lymphoproliferative Disorder
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma

Interventions: Drug: tanespimycin
Drug: belinostat
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2006-07-20

Last Posted Date: 2013-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00354185

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: sorafenib tosylate
Drug: tanespimycin
Other: laboratory biomarker analysis
Other: pharmacological study
Procedure: magnetic resonance imaging

First Posted Date: 2005-07-21

Last Posted Date: 2014-06-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT00121264

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: tanespimycin
Drug: irinotecan hydrochloride

First Posted Date: 2005-07-13

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT00119236

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate
Stage IV Prostate Cancer
Recurrent Prostate Cancer

Interventions: Drug: tanespimycin
Other: laboratory biomarker analysis

First Posted Date: 2005-07-11

Last Posted Date: 2017-04-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT00118092

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

Phase 2

Completed

Conditions: Recurrent Thyroid Cancer
Stage IV Follicular Thyroid Cancer
Stage IV Papillary Thyroid Cancer
Thyroid Gland Medullary Carcinoma

Interventions: Drug: tanespimycin

First Posted Date: 2005-07-11

Last Posted Date: 2017-02-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 41

Registration Number: NCT00118248

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Anaplastic Large Cell Lymphoma
Recurrent Adult Hodgkin Lymphoma
Recurrent Mantle Cell Lymphoma

Interventions: Drug: tanespimycin

First Posted Date: 2005-07-11

Last Posted Date: 2014-05-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 22

Registration Number: NCT00117988

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

Phase 1

Terminated

Conditions: Adult Acute Basophilic Leukemia
Adult Acute Eosinophilic Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)

Interventions: Drug: tanespimycin
Drug: bortezomib

First Posted Date: 2005-02-08

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 74

Registration Number: NCT00103272

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

Phase 1

Terminated

Conditions: B-cell Chronic Lymphocytic Leukemia
Prolymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia

Interventions: Drug: tanespimycin
Biological: rituximab

First Posted Date: 2004-12-08

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00098488

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Basophilic Leukemia
Adult Acute Eosinophilic Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Interventions: Drug: tanespimycin
Drug: cytarabine

First Posted Date: 2004-12-08

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT00098423

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy